almagate has been researched along with Choroid Neovascularization in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 63 (65.63) | 29.6817 |
| 2010's | 33 (34.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia Parodi, M; Brue, C; Cappello, E; Di Bartolo, E; Furino, C; Giuffrida, S; Imparato, M; Reibaldi, M | 1 |
| Chilov, M; Nguyen, CL; Oh, LJ; Wei, J; Wong, E | 1 |
| Hawkins, BS; Krzystolik, MG; Lindsley, K; Solomon, SD; Vedula, SS | 2 |
| Kitagawa, T; Yuzawa, M | 2 |
| Akagi-Kurashige, Y; Kumagai, K; Matsuda, F; Miyake, M; Nakanishi, H; Nakata, I; Oishi, A; Tsujikawa, A; Yamada, R; Yamashiro, K; Yoshimura, N | 1 |
| Feucht, N; Huebner, M; Lohmann, C; Maier, M | 1 |
| Adamis, AP; Buggage, R; Cunningham, E; Goldbaum, M; Guyer, D; Katz, B; Masonson, H; Patel, M; Singerman, LJ | 1 |
| Criswell, MH; Hu, WZ; Li, R; Margaron, P; Steffens, TJ | 1 |
| Chang, LK; Chiang, A; Sarraf, D; Yu, F | 1 |
| Atmani, K; Coscas, F; Coscas, G; Soubrane, G | 1 |
| Qureshi, SH; van Wijngaarden, P | 1 |
| Tano, Y | 1 |
| Adelman, RA; Lu, F | 1 |
| Brown, GC; Brown, MM; Ho, AC; Huang, SS; Ip, MS; Recchia, FM; Scott, IU | 1 |
| Calvo-González, C; Donate-López, J; García-Feijoó, J; García-Sánchez, J; Leila, M; Molina Guilabert, I; Reche-Frutos, J | 1 |
| Kocabora, MS; Ozbilen, KT; Serefoglu, K | 1 |
| Bakri, SJ; Depperschmidt, E; Fung, AE; Gibson, A; Palanki, R | 1 |
| Garcia-Layana, A; Giraldez, J; Hernandez-Pastor, LJ; Ortega, A | 2 |
| Hughes, MS; Sang, DN; Shah, GK | 1 |
| Ciulla, TA; Rosenfeld, PJ | 1 |
| Csaky, K; Do, DV | 1 |
| Barbosa, A; Beatty, S; Campos, A; Eldem, B; Faria, R; Feucht, N; Grisanti, S; Hykin, P; Kadayifçilar, S; Kolar, P; Maestroni, L; Olea, JL; Rito, L; Saeed, A; Silva, R; Sivaprasad, S; Staurenghi, G | 1 |
| Bressler, SB | 1 |
| Bass, EB; Bressler, NM; Cassard, SD; Gower, EW; Schein, OD | 1 |
| Nelson, M | 1 |
| Goss, TF; Weber, PA; Wirostko, BM; Xu, X; Zlateva, G | 1 |
| Capone, A; Quiram, P; Sund, N; Vinekar, A | 1 |
| Wiwanitkit, V | 1 |
| Chen, FK; Ikeji, F; Keane, PA; Ouyang, Y; Patel, PJ; Sadda, SR; Tufail, A; Walsh, AC | 1 |
| Dietzel, M; Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Spital, G | 1 |
| Bolz, M; Mitsch, C; Pollreisz, A; Schmidt-Erfurth, U | 1 |
| Manfreda, I; Uhlig, CE | 1 |
| Cennamo, G; Cesarano, I; D'Amico, G; De Crecchio, G; Finelli, M; Forte, R | 1 |
| Hovorka, M | 1 |
| Matthé, E; Sandner, D | 1 |
| Kertes, PJ; Kohly, RP; Lam, WC; Muni, RH | 1 |
| Babish, JD; Brechner, RJ; Caplan, S; Rosenfeld, PJ | 1 |
| Arcidiacono, B; Costagliola, C; Morescalchi, F; Parmeggiani, F; Semeraro, F | 1 |
| Cekiç, O; Göçmez, E; Kocabora, MS | 1 |
| de Oliveira Dias, JR; Farah, ME; Magalhães, O; Maia, M; Penha, FM; Rodrigues, EB | 1 |
| Aihara, Y; Fukuda, T; Hashimoto, H; Yanagi, Y | 1 |
| Heussen, FM; Keane, PA; Mokwa, N; Ouyang, Y; Patel, PJ; Sadda, SR; Tufail, A; Walsh, AC | 1 |
| Dombi, T; Kwok, KK; Sultan, MB | 1 |
| Buggage, R; Chakravarthy, U; Kwok, K; Staurenghi, G; Tressler, CS | 1 |
| Chiosi, F; Costagliola, C; DellʼOmo, R; Menzione, M; Parmeggiani, F; Rinaldi, M; Romano, MR; Semeraro, F | 1 |
| Adamis, AP; Cunningham, ET; Feinsod, M; Gragoudas, ES; Guyer, DR | 1 |
| Blaise, P; Foidart, JM; Rakic, JM | 1 |
| Arias Barquet, L | 1 |
| Haamann, PH; la Cour, M; Larsen, M; Lund-Andersen, H; Sander, B; Villumsen, JE | 1 |
| Pauleikhoff, D | 1 |
| Mones, J | 1 |
| Fraunfelder, FW | 1 |
| Kourlas, H; Schiller, DS | 1 |
| Apte, RS; Blinder, KJ; Dhalla, MS; Hariprasad, SM; Tewari, A | 1 |
| Adamis, AP; Cunningham, ET; D'Amico, DJ; Guyer, DR; Katz, B; Masonson, HN; Patel, M | 1 |
| Adamis, AP; Chakravarthy, U; Cunningham, ET; Goldbaum, M; Guyer, DR; Katz, B; Patel, M | 1 |
| Bandello, F; Chakravarthy, U; Chong, V; Creuzot-Garcher, C; Dimitrakos, SA; Korobelnik, JF; Larsen, M; Monés, J; Pauleikhoff, D; Pournaras, CJ; Soubrane, G; Staurenghi, G; Virgili, G; Wolf, S | 1 |
| Adamis, AP; Lu, M | 1 |
| Fekrat, S; Williams, AJ | 1 |
| Bennett, MD; Yee, W | 1 |
| Chaudhry, NA; Colina, J; Haffner, G; Liggett, PE; Tom, D | 1 |
| Del Priore, LV; Shah, AR | 1 |
| Lin, RC; Rosenfeld, PJ | 1 |
| Bailey, C; Imrie, FR | 1 |
| Azar, AE; Fuller, JJ; Muller, BA; Russell, SR; Steffensmeier, AC | 1 |
| Brown, GC; Brown, HC; Brown, MM; Kindermann, S; Sharma, S | 1 |
| Kaiser, PK | 1 |
| Guyatt, G; Heels-Ansdell, D; Kelly, S; Mills, E | 1 |
| Clegg, AJ; Colquitt, J; Jones, J; Takeda, AL | 1 |
| Adamis, AP; Apte, RS; Masonson, H; Modi, M; Patel, M; Whitfield, L | 1 |
| Leys, A; Patel, M; Shah, SN; Zlateva, G | 1 |
| Brubaker, JW; Collins, AT; Joeres, S; Kaplowitz, K; Romano, PW; Sadda, SR; Updike, PG; Walsh, AC | 1 |
| Goldstein, M; Leibovitch, I; Loewenstein, A; Waisbourd, M | 1 |
| Vinores, SA | 1 |
| Dayani, PN; Holekamp, NM; Siddiqi, OK | 1 |
| Hassan, TS; Quiram, PA; Williams, GA | 1 |
| Chang, LK; Flaxel, CJ; Lauer, AK; Sarraf, D | 1 |
| Bornfeld, N; Jurklies, B; Lipski, A | 1 |
| Novack, GD | 1 |
| Calvo-González, C; Donate-López, J; Fernández-Pérez, C; García-Feijoó, J; Garcia-Sánchez, J; Leila, M; Reche-Frutos, J | 1 |
| Apte, RS | 1 |
| Eter, N; Meyer, CH | 1 |
| Adamis, AP; Bradley, J; Calias, P; Cook, G; Dowie, T; Ganley, M; Ju, M; Lange, N; Mailhos, C; Robinson, GS; Shima, DT | 1 |
| Eter, N; Helb, HM; Meyer, CH | 1 |
| Meyer, CH | 1 |
| Maiti, A; Natarajan, S; Uparkar, M | 1 |
| Krzystolik, MG; Vedula, SS | 1 |
| Clegg, AJ; Colquitt, JL; Jones, J; Price, A; Takeda, A; Tan, SC | 1 |
| Gajdzik-Gajdecka, U; Smuzyńska, M; Trzciakowski, K; Wykrota, H | 1 |
| Pieramici, DJ; Rabena, MD | 1 |
24 review(s) available for almagate and Choroid Neovascularization
| Article | Year |
|---|---|
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Middle Aged; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity | 2019 |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Middle Aged; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity | 2014 |
Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Macular Degeneration; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A | 2008 |
Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy; Humans; Macular Degeneration; Ranibizumab; Technology Assessment, Biomedical; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2008 |
Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2009 |
Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Approval; Humans; Macular Degeneration; Ranibizumab; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2009 |
Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A | 2009 |
Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Ligands; Macular Degeneration; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Cytokines; Drug Therapy, Combination; Eye Proteins; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Infliximab; Intravitreal Injections; Molecular Targeted Therapy; Nerve Growth Factors; Platelet-Derived Growth Factor; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Serpins; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2011 |
neovascular age-related macular degeneration: Natural History and Treatment Outcomes.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Fluorescein Angiography; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Prognosis; Treatment Outcome; Visual Acuity | 2005 |
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
Topics: Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Treatment Outcome | 2006 |
Molecular biology of choroidal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Biomarkers; Choroid; Choroidal Neovascularization; Disease Progression; Humans; Injections; Molecular Biology; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2006 |
Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Blindness; Choroidal Neovascularization; Disease Progression; Exudates and Transudates; Humans; Macula Lutea; Macular Degeneration; Photochemotherapy; Pregnadienediols; Randomized Controlled Trials as Topic; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Antiangiogenic therapy in neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haplorhini; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Porphyrins; Prognosis; Ranibizumab; Risk Assessment; Treatment Outcome; Verteporfin; Visual Acuity | 2007 |
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Delivery Systems; Humans; Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Pegaptanib in the treatment of wet, age-related macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Macular Degeneration; Vascular Endothelial Growth Factor A | 2006 |
Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Laser Coagulation; Macular Degeneration; Porphyrins; Prevalence; Ranibizumab; Verteporfin | 2008 |
Pegaptanib sodium for the treatment of age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Protein Isoforms; Vascular Endothelial Growth Factor A | 2008 |
[Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Choroidal Neovascularization; Clinical Trials, Phase III as Topic; Fluorescein Angiography; Follow-Up Studies; Humans; Injections; Macular Degeneration; Meta-Analysis as Topic; Monitoring, Physiologic; Multicenter Studies as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Verteporfin; Vision Tests; Visual Acuity; Vitreous Body | 2008 |
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Middle Aged; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2008 |
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Contrast Sensitivity; Cost-Benefit Analysis; Drug Costs; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Visual Acuity | 2008 |
18 trial(s) available for almagate and Choroid Neovascularization
| Article | Year |
|---|---|
[Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study].
Topics: Adult; Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Male; Middle Aged; Myopia, Degenerative; Pilot Projects; Prospective Studies; Retinal Vessels; Treatment Outcome | 2013 |
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Intraocular Pressure; Macular Degeneration; Male; Tonometry, Ocular; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
[Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration].
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Injections; Macular Degeneration; Male; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Contrast Sensitivity; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Reading; Retina; Subretinal Fluid; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
[Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Macular Degeneration; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: findings of the PERSPECTIVES study.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Early Diagnosis; Humans; Macular Degeneration; Middle Aged | 2012 |
Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fovea Centralis; Humans; Intravitreal Injections; Male; Middle Aged; Myopia, Degenerative; Pilot Projects; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Visual Field Tests; Visual Fields | 2013 |
Pegaptanib for neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Prospective Studies; Radiography; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2004 |
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Treatment Outcome; Vascular Endothelial Growth Factors; Visual Acuity; Vitreous Body | 2005 |
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Fluorescein Angiography; Humans; Indocyanine Green; Injections; Macular Degeneration; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Drug Administration Schedule; Humans; Injections; Macular Degeneration; Middle Aged; Prospective Studies; Research Design; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Pressure; Choroidal Neovascularization; Double-Blind Method; Female; Half-Life; Humans; Immunoglobulin G; Immunoglobulin M; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Prospective Studies; Proteinuria; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
Quality of life in patients with age-related macular degeneration: results from the VISION study.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Middle Aged; Quality of Life; Sickness Impact Profile; Visual Acuity | 2008 |
Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Combined Modality Therapy; Female; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2008 |
[Pegaptanib sodium in treatment of choroidal neovascularization secondary to age-related macular degeneration. One year results].
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Prospective Studies; Treatment Outcome | 2007 |
54 other study(ies) available for almagate and Choroid Neovascularization
| Article | Year |
|---|---|
Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Macular Degeneration; Male; Retrospective Studies; Thromboembolism; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2018 |
Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Axial Length, Eye; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Genotype; Humans; Male; Middle Aged; Myopia, Degenerative; Ophthalmoscopy; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ranibizumab; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |
[Comparison of 1-year treatment outcome of intravitreal pegaptanib sodium versus bevacizumab for myopic choroidal neovascularization].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Humans; Intravitreal Injections; Male; Middle Aged; Myopia; Treatment Outcome | 2013 |
[Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Administration Schedule; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Retreatment; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Glucocorticoids; Injections; Laser Coagulation; Male; Rats; Rats, Inbred BN; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Macular Degeneration; Male; Predictive Value of Tests; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Pigment Epithelium; Retinal Vessels; Retrospective Studies; Risk Assessment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2008 |
Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Compassionate Use Trials; Female; Fluorescein Angiography; Humans; Macular Degeneration; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescein Angiography; Injections; Light Coagulation; Macular Degeneration; Ranibizumab; Rats; Rats, Inbred BN; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
Intravitreal pegabtanib sodium in choroidal neovascularization secondary to angioid streaks.
Topics: Adult; Angiogenesis Inhibitors; Angioid Streaks; Aptamers, Nucleotide; Choroidal Neovascularization; Edema; Fluorescein Angiography; Humans; Injections; Male; Retinal Detachment; Retinal Diseases; Tomography, Optical Coherence; Vitreous Body | 2009 |
Intravitreal silicone oil droplets following pegaptanib injection.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Eye Diseases; Eye Foreign Bodies; Humans; Injections; Mass Spectrometry; Silicon; Silicone Oils; Ultrasonography; Vascular Endothelial Growth Factor A; Vitreous Body | 2010 |
Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Guidelines as Topic; Humans; Macular Degeneration; Ophthalmology; Periodicals as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Publishing; Quality Control; Randomized Controlled Trials as Topic; Ranibizumab; Verteporfin | 2009 |
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Humans; Injections; Insurance, Health, Reimbursement; Macular Degeneration; Markov Chains; Middle Aged; Photochemotherapy; Quality of Life; Ranibizumab; Reproducibility of Results; Spain; Visual Acuity | 2008 |
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Costs and Cost Analysis; Health Care Costs; Health Services Research; Humans; Macular Degeneration; Markov Chains; Quality-Adjusted Life Years; Ranibizumab; Spain; Visual Acuity | 2010 |
Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Topics: Adverse Drug Reaction Reporting Systems; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Databases, Factual; Drug Administration Routes; Humans; Macular Degeneration; Medical Records Systems, Computerized; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Cohort Studies; Humans; Intravitreal Injections; Macular Degeneration; Retrospective Studies; Vascular Endothelial Growth Factors; Visual Acuity | 2010 |
A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Humans; Injections; Macular Degeneration; Models, Economic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quality of Life; Quality-Adjusted Life Years; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity; Vitreous Body | 2010 |
Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2010 |
Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Community Medicine; Drug Administration Schedule; Exudates and Transudates; Female; Fovea Centralis; Humans; Injections, Intraocular; Macular Degeneration; Male; Medical Records; Middle Aged; Professional Practice; Retrospective Studies; Treatment Outcome; United States; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
Choroidal neovascular membrane in persistent fetal vasculature syndrome managed with intravitreal pegaptanib sodium in an infant.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Fluorescein Angiography; Humans; Infant; Injections; Male; Persistent Hyperplastic Primary Vitreous; Postoperative Complications; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Vitreous Body | 2010 |
Ranibizumab vs. pegaptanib: a cost-effectiveness study?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Costs and Cost Analysis; Health Care Costs; Health Services Research; Humans; Macular Degeneration; Quality-Adjusted Life Years; Ranibizumab; Visual Acuity | 2010 |
[Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Intravitreal Injections; Macular Degeneration; Male; Ophthalmoscopes; Ranibizumab; Retina; Retinal Detachment; Retinal Neovascularization; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Antivascular endothelial growth factors in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Injections, Intraocular; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2010 |
[Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Combined Modality Therapy; Fluorescein Angiography; Humans; Injections, Intraocular; Male; Photochemotherapy; Ranibizumab; Retina; Retreatment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body; Wet Macular Degeneration | 2010 |
Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Prognosis; Retreatment; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
[The change of the anti-VEGF agent in the treatment of exceptionally active choroidal neovascular membrane in age-related macular degeneration].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Substitution; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factors | 2010 |
[Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Humans; Intravitreal Injections; Male; Myocardial Infarction; Ranibizumab; Retrospective Studies; Risk Factors; Stents; Stroke; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Child; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Ranibizumab; Retreatment; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy; Drug Utilization Review; Fee-for-Service Plans; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Middle Aged; Porphyrins; Ranibizumab; Retrospective Studies; United States; Vascular Endothelial Growth Factor A; Verteporfin | 2011 |
Management of CNV in angioid streaks by intravitreal use of specific anti-VEGF165 Aptamer (pegaptanib sodium): long-term results.
Topics: Adult; Angiogenesis Inhibitors; Angioid Streaks; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
Topics: Aged; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Asian People; Choroidal Neovascularization; Cost-Benefit Analysis; Humans; Macular Degeneration; Male; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A | 2011 |
Pegaptanib and age-related macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Dose-Response Relationship, Drug; Humans; Injections; Macular Degeneration; Oligonucleotides; Vitreous Body | 2005 |
[Antiangiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Eye Proteins; Humans; Macular Degeneration; Nerve Growth Factors; Photochemotherapy; Ranibizumab; Serpins; Vascular Endothelial Growth Factor A | 2005 |
New perspectives on the treatment of age-related macular degeneration.
Topics: Age Factors; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Combined Modality Therapy; Genetic Therapy; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy | 2005 |
Pegaptanib for wet macular degeneration.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Light Coagulation; Macular Degeneration; Molecular Structure; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A; Vitamins | 2005 |
Retinal pigment epithelial tear following intravitreal pegaptanib sodium.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Indocyanine Green; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Visual Acuity | 2006 |
[Comments on current therapeutic possibilities for neovascular age-related macula degeneration].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Germany; Glucocorticoids; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Porphyrins; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnadienediols; Ranibizumab; Triamcinolone; Verteporfin | 2006 |
Evolving European guidance on the medical management of neovascular age related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Evidence-Based Medicine; Humans; Macular Degeneration; Photochemotherapy; Pregnadienediols; Ranibizumab; Treatment Outcome; Triamcinolone Acetonide | 2006 |
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vitreous Body | 2006 |
Pegaptanib for myopic choroidal neovascularization in a young patient.
Topics: Adult; Angiogenesis Inhibitors; Aptamers, Nucleotide; Capillary Permeability; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Myopia, Degenerative; Prognosis; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.
Topics: Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Therapy, Combination; Fluorescein Angiography; Glucocorticoids; Humans; Injections; Photochemotherapy; Photosensitizing Agents; Porphyrins; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity; Vitreous Body | 2006 |
New treatments for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
Vitreous injections of pegaptanib sodium triggering allergic reactions.
Topics: Aged, 80 and over; Anaphylaxis; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Diphenhydramine; Drug Hypersensitivity; Drug Therapy, Combination; Epinephrine; Humans; Injections; Male; Methylprednisolone; Urticaria; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; Economics, Medical; Evidence-Based Medicine; Fovea Centralis; Health Care Costs; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quality of Life; Quality-Adjusted Life Years; Verteporfin; Visual Acuity | 2007 |
Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Humans; Injections; Macular Degeneration; Male; Retina; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
[Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Macular Degeneration; Ophthalmology; Photochemotherapy; Porphyrins; Pregnadienediols; Ranibizumab; Societies, Medical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Verteporfin | 2007 |
Safety of intravitreal injections in patients receiving warfarin anticoagulation.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aptamers, Nucleotide; Aspirin; Celecoxib; Choroidal Neovascularization; Drug Therapy, Combination; Eye Hemorrhage; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sulfonamides; Vascular Endothelial Growth Factor A; Vitreous Body; Warfarin | 2007 |
Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
RPE tears after pegaptanib treatment in age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Postoperative Complications; Retinal Perforations; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Electroretinography; Exudates and Transudates; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Retina; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
Topics: Angiogenesis Inhibitors; Anticoagulants; Aptamers, Nucleotide; Aspirin; Choroidal Neovascularization; Drug Therapy, Combination; Eye Hemorrhage; Humans; Incidence; Injections; Macular Degeneration; Risk Factors; Vascular Endothelial Growth Factor A; Vitreous Body; Warfarin | 2008 |
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
Topics: Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Chromatography, High Pressure Liquid; Cornea; Corneal Neovascularization; Disease Models, Animal; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Photochemotherapy; Photosensitizing Agents; Porphyrins; RNA, Messenger; Thromboplastin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Verteporfin | 2008 |
[Introduction to the topic: anti-VEGF therapy in the management of AMD].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Endophthalmitis; Humans; Injections; Macular Degeneration; Postoperative Care; Ranibizumab; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Correspondence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Injections; Macular Degeneration; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Anti-VEGF therapy: comparison of current and future agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Forecasting; Humans; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2008 |